A5002146164- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Mast cells and histamine
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- RNA modifications and cancer
- melanin and skin pigmentation
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Cytokine Signaling Pathways and Interactions
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- RNA and protein synthesis mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
- Polyamine Metabolism and Applications
Hadassah Medical Center
2016-2025
Hebrew University of Jerusalem
2014-2025
Hadassah
2006-2023
Centre Hospitalier Universitaire de Montpellier
2023
Université de Montpellier
2023
College of Management Academic Studies
2023
Hadassah Academic College
2021-2022
University Medical Center
2019
Sheba Medical Center
2011
Tel Aviv Sourasky Medical Center
2011
The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.
Abstract Author Summary Background. Disulfiram, an alcohol aversion agent, has been in use for >50 years. Numerous authors have reported anticancer effect of this drug vitro and mouse models. More recently, several reports claimed that disulfiram also possesses anti-stem cell activity. We set out to obtain initial data regarding the safety combining with chemotherapy possible effectiveness a combination regimen non-small lung cancer (NSCLC). Methods. This phase II, multicenter,...
The accumulation of circulating low-density neutrophils (LDN) has been described in cancer patients and associated with tumor-supportive properties, as opposed to the high-density (HDN). Here we aimed evaluate clinical significance LDN lung patients, further assessed its diagnostic vs prognostic value. Using mass cytometry (CyTOF), identified major subpopulations within LDN/HDN subsets determined phenotypic modulations these along tumor progression. were highly enriched (LD) fraction...
Patients with advanced non-small-cell lung cancer (NSCLC) treated immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The vaccine OSE2101 may invigorate antitumor-specific responses ICB failure. objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. a two-step open-label study the compared standard-of-care (SoC) chemotherapy (CT). human leukocyte antigen (HLA)-A2-positive NSCLC...
Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients cancers treated osimertinib and selpercatinib for fusion-mediated has not previously published.
Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this subgroup.Patients with stage IV that progressed after clinical benefit on erlotinib/gefitinib and/or had activating EGFR or ERBB2 mutations, exhausted other treatments, and were ineligible afatinib trials enrolled in a named patient use program, receiving 30 50 mg/d compassionate basis within routine practice. Efficacy safety retrospectively...
Castrate-resistant prostate cancer (CRPC) often shows histological evidence of neuroendocrine differentiation (NED). To evaluate the extent NED in patients with CRPC, we used PET/CT Ga-[DOTA-Tyr]-octreotate (Ga-DOTA-TATE), a somatostatin analog that binds receptor 2 high affinity. This radiotracer is imaging tumors.Twelve (mean age, 65 [SD, 12] years) CRPC were studied. Their mean prostate-specific antigen level at scanning was 85.6 (SD, 144.6) ng/mL. images obtained after injection 120 to...
Both pembrolizumab (P) and combination of with platinum-based chemotherapy (PCT) represent standard 1st-line options for advanced non-small cell lung cancer (aNSCLC) PD-L1 tumor proportion score (TPS) ≥50%. The two strategies have never been compared in a randomized trial. 256 consecutive patients EGFR/ALK/ROS1-wild-type TPS ≥50% aNSCLC receiving P (group P, n = 203) or PCT PCT, 53) as treatment were identified the electronic databases 4 Israeli centers. Time-to-treatment discontinuation...
PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination chemotherapy. This approach fails to account individual patient variability and host immune factors often results less-than-ideal outcomes. To address limitations current guidelines, we developed subsequently blindly validated a machine learning algorithm using pretreatment plasma...
Introduction Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or combination with chemotherapy remains widely varied and existing biomarkers limited predictive value. We present an analysis ENLIGHT-DP, a novel transcriptome-based biomarker directly from histopathology slides, patients adenocarcinoma (LUAD) treated platinum-based chemotherapy. Methods retrospectively scanned...
Microphthalmia (<i>mi</i>) is a transcription factor that plays major role in the regulation of growth and function mast cells melanocytes. Association of<i>mi</i> with other proteins critical step <i>mi</i>-mediated transcriptional activation. We found protein kinase C-interacting 1 (PKCI) specifically associated with<i>mi</i> yeast two-hybrid screening. Immunoprecipitation from quiescent rat basophilic leukemic or mouse melanocytes resulted specific co-immunoprecipitation PKCI. This...
<i>In vitro</i> and <i>in vivo</i>evidence suggest that microphthalmia transcription factor (MITF) plays a key regulatory role in tissue-specific gene regulation several cell types, including melanocytes, osteoclasts, mast cells. A yeast two-hybrid search, using portion of nonmutated MITF as the bait screening library, resulted isolation STAT3 inhibitor, PIAS3. PIAS3 is transcriptional inhibitor acts by specifically inhibiting STAT3's DNA binding activity. We found it can directly associate...